Fig. 3
Spleen [68Ga]Pentixafor uptake does not correlate with clinical outcomes in solid tumor patients. A Kaplan–Meier survival curves of progression-free survival (PFS) and overall survival (OS) of all solid tumor patients in the study separated by the median into two groups of low and high spleen-to-liver ratios (SUVmaxSpleen/SUVmeanLiver), PFS: low, n = 61, high, n = 58; OS: low, n = 61, high, n = 54. B Comparison of spleen-to-liver ratios (SUVmaxSpleen/SUVmeanLiver) with remission status of all patients, complete remission (CR), n = 2; partial remission (PR), n = 9; stable disease (SD), n = 15; progressive disease (PD), n = 51. All statistical analyses were performed using log rank (Mantel–Cox) test (A) and one-way ANOVA with Tukey’s correction for multiple comparisons (B). P values as indicated on the graphs